Russia Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Russia Breast Cancer Therapeutics Market Analysis

$ 3999

The Russia breast cancer therapeutics market is expected to grow from $297 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The major market drivers in Russia include the rising prevalence of breast cancer and the expansion of treatment alternatives like new targeted therapies and hormonal therapies for breast cancer. The market is segmented by therapy, by cancer type, and by distribution channel. Some major companies in Russia's breast cancer therapeutics market are Alpen Pharma, Bristol-Myers Squibb, and Eli Lilly.

ID: IN10RUPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Russia AUTHOR: Parul Choudhary

Buy Now

Russia Breast Cancer Therapeutics Market Executive Analysis

The Russia breast cancer therapeutics market size is at around $297 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. In 2020, Russia's overall public spending on healthcare was close to $55 Bn. Contributions to the Federal Obligatory Medical Insurance Fund (FOMIF) made up the majority of the sum. The FOMIF was projected to finance healthcare to the amount of $45 Bn in 2024. In 2020, Russia's consolidated budget's health spending accounted for 4.6 % of the country's GDP, up from 3.5 % the year before. The largest nation in the world is the Russian Federation. The nation's population, which totals about 140 Mn, is dispersed unevenly. The availability of primary and specialist medical care is hence highly spatially unequal in Russia. Along with unhealthy behaviour, inadequate funding and ineffective resource allocation in the healthcare system may also contribute to population health that is below par. 5.3% of the country's GDP was spent on health care overall, which is significantly less than the average for the Organization for Economic Cooperation and Development. Private health care spending is generally made out of pocket, and voluntary health insurance makes up a very small portion of it.

Breast cancer is the most prevalent type of cancer in Russian women and the main reason for oncological mortality there. Only 60% of breast cancer cases are discovered when they are localised. Russia has a lower five-year survival rate for breast cancer patients than the USA. Breast cancer-targeted therapies use substances or medications that prevent the spread of cancer by disrupting the activity of particular molecules necessary for the survival and multiplication of tumour cells. Breast cancer cells may overexpress certain receptors that, when triggered, can start downstream signalling that causes the production of genes necessary for cancer cell migration, angiogenesis, proliferation, growth, and survival. Although some of the genetic mutations and epigenetic changes in molecular pathways have been understood, it is sometimes necessary to combine several pathway blockades in order to achieve successful treatment results because the rapid acquisition of resistance in breast cancer-targeted therapies seems to limit the effectiveness of treatment. In 2019, Russia performed the first Alpha daRT procedure for the treatment of metastatic breast cancer in which alpha particles were used to target the cancer cells as they are the most aggressive form of radiation. Members of the Russian oncology team that took part in the Alpha DaRT trial believe that this new method's novel mechanism of action may provide patients with slim odds of survival hope.

russia breast cancer therapeutics markets

Market Dynamics

Market Growth Drivers

The Russia breast cancer therapeutics market growth rate is being accelerated by factors such the ongoing increase in cancer cases in Russia, the expansion of treatment alternatives, and the expansion of R&D activities in some of the most recognised drug laboratories in the world. The market is expanding more rapidly thanks to the introduction of numerous medication therapeutics alternatives for breast cancer available in Russia.

Market Restraints

Russia has issues with the implementation of advanced surgical therapeutics and the low pay for medical professionals. Primary health state clinics and centres of excellence typically get an unequal distribution of medical resources along with insufficient reimbursement policies further limiting the growth of Russia breast cancer therapeutics market.

Competitive Landscape

Key Players

Pharmasyntez (RUS)
NovaMedica (RUS)
WERTEKS (RUS)
Alpen Pharma (RUS)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

The right to free healthcare is guaranteed by the Russian Constitution for all citizens and residents. State funding for this comes from the Federal Compulsory Medical Insurance Fund. Through Russia's Obligatory Medical Insurance (OMI), every working resident and citizen of Russia is provided with free state health insurance. Employer contributions and payroll taxes are used to pay for it. OMI-based care is robust. All procedures requiring an overnight hospital stay, such as those related to breast cancer surgery, are covered as part of the cost of inpatient care. Employers contribute between 2% and 3% of employee earnings to a social tax, which goes toward supporting the healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.